| Name | Title | Contact Details |
|---|
Second Sight is a Sylmar, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid`s drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid has initiated the Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a Phase 1 trial in adolescents with Angelman and Fragile X syndrome to identify doses suitable for younger patients.
Central California Blood Center is a Fresno, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At Tegria, we believe that the right technology and tools can help make care more effective for more people. Launched in 2020 with support from Providence, one of the country`s largest health systems, Tegria combines innovative technologies and services to create powerful solutions that simplify healthcare for everyone involved. We built Tegria to make a difference, not only for our customers, but for our communities. We deliver complete solutions to streamline the process of receiving and delivering care, from first visit to follow-up and beyond.
Prematics, Inc is a Mclean, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.